| ID ▲ | Analyse | Domein | Recipiënt | Uitvoering | LTAT (uren (dagen)) | Accred. | LOINCeenheid (1) | LOINCeenheid (2) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 903 | FSH (M/V) | Serum |
– | – U/L | – | › | ||||
| 1270 | Factor II dosage | Citraat |
1× per 2 weken | – | 3289-6 % | – | › | |||
| 1272 | Factor V dosage | Citraat |
tenminste 1× per week | 218 (9,1) | – | 3193-0 % | – | › | ||
| 1274 | Factor VII dosage Proconvertine | Citraat |
1× per 2 weken | 521 (21,7) | – | 3198-9 % | – | › | ||
| 1292 | Factor XI dosage | Citraat |
1× per 2 weken | 422 (17,6) | – | 3226-8 % | – | › | ||
| 1294 | Factor XII dosage Hageman Factor | Citraat |
– | 3232-6 % | – | › | ||||
| 1296 | Factor XIII screening | Citraat |
– | 3239-1 | – | › | ||||
| 1342 | anti-factor Xa | Citraat |
1× per week | 96 (4) | – | 3216-9 IU/ml | – | › | ||
| 1343 | anti-Xa Rivaroxaban Anti-Xa (New Oral AntiCoagulants) | Citraat |
1× per week | – | 74871-5 ng/mL | – | › | |||
| 1344 | Anti-Xa Apixaban | Citraat |
maandag t/m vrijdag | 18 (0,7) | – | 74214-8 ng/mL | – | › | ||
| 1404 | Heredit. hemochromatose | EDTA |
– | – | – | › | ||||
| 1423 | Kp b antigeen (KEL4) | EDTA |
– | 1108-0 | – | › | ||||
| 1449 | Mucoviscidose CF, CFTR, Cystic Fibrosis Transmembrane conductance Regulator-gen | EDTA |
724 (30,1) | – | – | – | › | |||
| 1451 | Fragile X syndroom FMR1, Fragile X Mental Retardation 1-gen | EDTA |
– | – | – | › | ||||
| 1459 | HLA-DQB1/DRB1 (narcolep) | EDTA |
1× per 2 weken | – | – | – | › | |||
| 1680 | Gluc-6-fosf.DH in RBC G6PD intraerythrocytair, Glucose-6-fosfaat dehydrogenase intraerythrocytair | EDTA |
tenminste 1× per week | 119 (4,9) | – | 2357-2 U/ml ery | – | › | ||
| 1683 | JAK2 V617F mutatie JAK2 mutatie, JAK2 mutation | EDTA |
1× per week | 424 (17,7) | – | – | – | › | ||
| 1684 | Pyruvaatkinase in RBC Pyruvaatkinase intraerythrocytair | EDTA |
459 (19,1) | – | 32552-2 U/g Hb | – | › | |||
| 1712 | MPN panel (12 genen) | EDTA |
1× per week | – | – | – | › | |||
| 1779 | Flowcytometrie ikv Immunofenotypering, Lymfocyten fenotypering | EDTA |
1 (0) | – | – | – | › | |||
| 2292 | Lange keten vetzuren | Serum |
– | 43677-4 | – | › | ||||
| 2293 | Famil.hyperlipidemie DNA apoB DNA, Familiale hypercholesterolemie, FH DNA | EDTA |
1× per 3 maanden | 221 (9,2) | – | – | – | › | ||
| 2295 | Fam. hypercholesterolemie | EDTA |
17 (0,7) | – | – | – | › | |||
| 2434 | CK iso-enzymen | Serum |
1× per maand | 969 (40,4) | – | 14680-3 U/l | – | › | ||
| 2592 | anti-IA2 antilichamen | Serum |
1× per maand | 909 (37,9) | – | 31209-0 U/mL | – | › | ||
| 2642 | Aminozuren kwantitatief | Heparine (Lithium-heparinebuis) |
2× per week | 303 (12,6) | – | 1913-3 | 35083-5 | › | ||
| 2655 | alfa Galactosidase | EDTA |
1× per week | 308 (12,9) | – | 1813-5 µmol/L/h | – | › | ||
| ● 2828 | p-Tau217 | EDTA |
– | – pg/mL | – | › | ||||
| 2902 | Complement C2 | Serum |
1× per 2 weken | 663 (27,6) | – | 4484-2 mg/l | – | › | ||
| ● 3003 | Complement C3d | EDTA |
1× per week | – | – g/L | 4493-3 g/L | › | |||
| 3008 | Hemopexine | Serum |
tenminste 1× per week | – | 2403-4 g/l | – | › | |||
| 3030 | Orosomucoiden Alfa-1 zure glycoproteïne | Serum |
2× per week | 201 (8,4) | – | 2685-6 g/L | – | › | ||
| 3216 | Myocard (1/100) Anti-myocard antistoffen | Serum |
1× per 3–4 weken | 70 (2,9) | – | 30537-5 | – | › | ||
| 3242 | anti-MAG As Myeline geassocieerde glycoproteïne antistoffen | Serum |
873 (36,4) | – | 31023-5 | – | › | |||
| 3258 | anti-ganglioside AS | Serum |
667 (27,8) | – | 82455-7 | – | › | |||
| 3277 | anti-MuSK As Anti-muscle specific kinase antistoffen | Serum |
278 (11,6) | – | 94273-0 | – | › | |||
| 3284 | Lp-PLA2 Lipoprotein-associated Phospholipase A2, PLAC-test | Serum |
tenminste 1× per week | 351 (14,6) | – | – nmol/min/mL | – | › | ||
| 3306 | anti-glycine receptor As | Serum |
319 (13,3) | – | 95722-5 | – | › | |||
| 3313 | Anti-nucleosomen | Serum |
– | 53014-7 U/ml | – | › | ||||
| 3314 | Anti-histonen | Serum |
– | 17380-7 U/ml | – | › | ||||
| 3316 | anti-VGCC (Ca kanaal As) | Serum |
412 (17,2) | – | 31024-3 pmol/L | – | › | |||
| 3415 | Hexokinase | EDTA |
2× per week | – | 49216-5 U/g Hb | – | › | |||
| 3416 | IgE mengsel voeding(fx24) | Serum |
1× per 1–2 weken | 100 (4,2) | – | 50655-0 kU/L | – | › | ||
| 3417 | IgE mengsel voeding(fx25) | Serum |
1× per 1–2 weken | 164 (6,8) | – | 50657-6 kU/L | – | › | ||
| 3418 | IgE mengsel schimmel(mx2) | Serum |
104 (4,3) | – | 30183-8 kU/L | – | › | |||
| 3421 | IgE mengsel grassen (gx2) | Serum |
1× per 1–2 weken | – | 30188-7 kU/l | – | › | |||
| 3427 | IgE mix ambrosia (wx209) | Serum |
– | 73710-6 kU/l | – | › | ||||
| 3432 | IgE mengsel bomen (tx1) | Serum |
96 (4) | – | 30184-6 kU/l | – | › | |||
| 3433 | IgE mengsel bomen (tx4) | Serum |
– | 24491-3 kU/l | – | › | ||||
| 3434 | IgE mengsel bomen (tx7) | Serum |
– | 30182-0 kU/l | – | › |
